KUALA LUMPUR: PMCK Bhd
is capitalising on rising healthcare demand in northern Malaysia, driven by a growing middle class, ageing population and greater health awareness.
The Private healthcare services provider plans to utilise RM50mil of the initial public offering (IPO) proceeds to finance the development of Putra Medical Centre (PMC) Kulim, a new private medical centre aimed at expanding its service coverage in Kedah.
Managing director Datuk Lee Gaik Cheng said Malaysia’s ageing population and the increasing prevalence of lifestyle-related diseases present significant opportunities for private healthcare providers.
“With our expansion plans, digitalisation initiatives and focus on preventive care, PMCK is well positioned to capture this growth and further strengthen our leadership in the northern region,” Lee said in a statement.
PMCK has begun participating in the Health Ministry’s Hospital Services Outsourcing Programme (HSOP), which is expected to boost patient flows in key specialties such as cardiology, radiology and surgery.
The group is also strengthening its service capacity through the recruitment of specialist consultants in high-demand areas and upgrading medical equipment to enhance operational efficiency.
In the first quarter ended July 31, PMCK posted a net profit of RM884,000 on revenue of RM21.8mil.
The group’s balance sheet strengthened after the IPO, with total assets rising to RM186.76mil as at July 31 from RM122.69mil on April 30. Cash and bank balances stood at RM82.31mil, boosted by RM59.97mil in proceeds from the public issue.
“Our maiden quarterly results underscore the resilience of our healthcare operations and the continued demand for quality private healthcare services in the northern region,” Lee said.
“The successful listing has provided us with the financial strength to accelerate our expansion plans, enhance service offerings and create sustainable long-term value for our shareholders.”
Barring unforeseen circumstances, PMCK also expects to receive a full settlement of RM6.01mil from a major supplier related to undelivered Covid-19 vaccines by the first quarter of 2026.
